Market Closed -
Nyse
16:00:02 2024-05-03 EDT
|
5-day change
|
1st Jan Change
|
42.45
USD
|
-0.14%
|
|
+0.12%
|
+1.60%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
4,218
|
2,341
|
2,822
|
1,626
|
914.1
|
1,595
|
Enterprise Value (EV)
1 |
4,218
|
2,341
|
2,822
|
1,626
|
914.1
|
1,595
|
P/E ratio
|
15
x
|
9.64
x
|
-7.29
x
|
27.9
x
|
35.8
x
|
38.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.3
x
|
3.63
x
|
5.14
x
|
2.9
x
|
1.6
x
|
2.58
x
|
EV / Revenue
|
6.3
x
|
3.63
x
|
5.14
x
|
2.9
x
|
1.6
x
|
2.58
x
|
EV / EBITDA
|
13,556,545
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
2.21
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
39,019
|
38,258
|
38,258
|
37,585
|
37,585
|
37,585
|
Reference price
2 |
108.1
|
61.20
|
73.75
|
43.26
|
24.32
|
42.45
|
Announcement Date
|
19-05-22
|
20-05-19
|
21-05-19
|
22-05-27
|
23-05-24
|
-
|
Fiscal Period: Marzo |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
669.9
|
644.8
|
549
|
561.3
|
573
|
618.1
|
EBITDA
|
311.1
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
292.5
|
246.5
|
145.1
|
124.9
|
17.71
|
-1.241
|
Operating Margin
|
43.67%
|
38.24%
|
26.44%
|
22.25%
|
3.09%
|
-0.2%
|
Earnings before Tax (EBT)
1 |
356.9
|
298
|
-391.1
|
77.86
|
38.21
|
53.54
|
Net income
1 |
281.8
|
244.2
|
-386.7
|
58.27
|
25.44
|
41.41
|
Net margin
|
42.06%
|
37.88%
|
-70.43%
|
10.38%
|
4.44%
|
6.7%
|
EPS
2 |
7.230
|
6.350
|
-10.12
|
1.550
|
0.6800
|
1.100
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-05-22
|
20-05-19
|
21-05-19
|
22-05-27
|
23-05-24
|
-
|
Fiscal Period: March |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
140.1
|
148.3
|
147.1
|
132
|
139
|
143.3
|
156.7
|
130.5
|
139.2
|
146.6
|
158.9
|
161.1
|
154.9
|
156.1
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
36.31
|
38.11
|
40.8
|
24.45
|
36.97
|
21.28
|
13.98
|
-6.815
|
1.279
|
9.274
|
-1.7
|
-1.098
|
1.032
|
0.91
|
Operating Margin
|
25.91%
|
25.69%
|
27.73%
|
18.52%
|
26.6%
|
14.85%
|
8.92%
|
-5.22%
|
0.92%
|
6.33%
|
-1.07%
|
-0.68%
|
0.67%
|
0.58%
|
Earnings before Tax (EBT)
1 |
39.14
|
-37.76
|
-16.08
|
29.42
|
39.5
|
25.02
|
16.05
|
-4.913
|
9.172
|
17.9
|
5.44
|
8.902
|
15.03
|
15.41
|
Net income
1 |
32.92
|
-29.79
|
-18.77
|
23.32
|
26.31
|
27.4
|
14.08
|
-2.813
|
7.265
|
6.913
|
10.03
|
6.676
|
11.27
|
11.56
|
Net margin
|
23.49%
|
-20.08%
|
-12.76%
|
17.67%
|
18.93%
|
19.13%
|
8.99%
|
-2.16%
|
5.22%
|
4.72%
|
6.31%
|
4.14%
|
7.28%
|
7.41%
|
EPS
2 |
0.8600
|
-0.7800
|
-0.5000
|
0.6200
|
0.7000
|
0.7300
|
0.3700
|
-0.0700
|
0.1900
|
0.1800
|
0.2700
|
0.1800
|
0.3000
|
0.3100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-01-27
|
21-05-19
|
21-07-27
|
21-10-28
|
22-01-27
|
22-05-27
|
22-07-27
|
22-10-27
|
23-01-24
|
23-05-24
|
23-07-27
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
48.90
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-05-22
|
20-05-19
|
21-05-19
|
22-05-27
|
23-05-24
|
-
|
Last Close Price
42.45
USD Average target price
43
USD Spread / Average Target +1.30% Consensus |
1st Jan change
|
Capi.
|
---|
| +1.60% | 1.6B | | +26.08% | 662B | | +21.85% | 546B | | -4.77% | 359B | | +16.97% | 323B | | +5.69% | 290B | | +13.68% | 234B | | +3.65% | 198B | | -11.12% | 194B | | +8.08% | 167B |
Other Pharmaceuticals
|